ReviewCurrent drug targets2007
Protein N-glycosylation in the baculovirus-insect cell system.
Review in Current drug targets, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 195 citations in OpenAlex.
- Trial
- Structural organization of TAM receptor ectodomains.The Biochemical journal · 2026Article
- Vaccination With Trichuris muris Poly-Cysteine and Histidine-Tailed Protein p43 Protects Against Chronic Infection.Parasite immunology · 2026Article
- Structure and functional divergence of the non-canonical BoNT-like toxin PG1 and PG2.Nature communications · 2026Article
- Production of mannosylated hrsACE2 by baculovirus expression system; the way to remove and redirect SARS-CoV-2 viral particles to macrophages.Biotechnology letters · 2026Article
- Rapid Production of Recombinant Human SLFN14 Ribonuclease and Stoichiometric Analysis by Mass Photometry.Journal of visualized experiments : JoVE · 2026Article
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- Cross-species protection suggestsInfection and immunity · 2025Article
- The Bioengineering of Insect Cell Lines for Biotherapeutics and Vaccine Production: An Updated Review.Vaccines · 2025Review
- Engineering the mossFrontiers in plant science · 2025Article
- Detection of Serum Antibodies Targeting the Marburg Virus Glycoprotein Using a Multiplex Immunoassay Platform.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Characterization of Site-Specific N- and O-Glycopeptides from Recombinant Spike and ACE2 Glycoproteins Using LC-MS/MS Analysis.International journal of molecular sciences · 2024Article
- Insect cell production of chimeric virus-like particles based on human immunodeficiency virus GAG proteins and yellow fever virus envelope protein.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Review
- Lysosomal enzyme binding to the cation-independent mannose 6-phosphate receptor is regulated allosterically by insulin-like growth factor 2.Scientific reports · 2024Article
- Baculovirus-Assisted Production ofPathogens (Basel, Switzerland) · 2024Article
- Structural and mechanistic characterization of bifunctional heparan sulfate N-deacetylase-N-sulfotransferase 1.Nature communications · 2024Article
- Dimerization of the CNNM extracellular domain.Protein science : a publication of the Protein Society · 2024Article
- Insect Cell-Based Expression of Cytoskeletal Motor Proteins for Single-Molecule Studies.Methods in molecular biology (Clifton, N.J.) · 2024Article
- XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.Scientific reports · 2023Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
One of the major advantages of the baculovirus-insect cell system is that it is a eukaryotic system that can provide posttranslational modifications, such as protein N-glycosylation. However, this is a vastly oversimplified view, which reflects a poor understanding of insect glycobiology. In general, insect protein glycosylation pathways are far simpler than the corresponding pathways of higher eukaryotes. Paradoxically, it is increasingly clear that various insects encode and can express more elaborate protein glycosylation functions in restricted fashion. Thus, the information gathered in a wide variety of studies on insect protein N-glycosylation during the past 25 years has provided what now appears to be a reasonably detailed, comprehensive, and accurate understanding of the protein N-glycosylation capabilities of the baculovirus-insect cell system. In this chapter, we discuss the models of insect protein N-glycosylation that have emerged from these studies and how this impacts the use of baculovirus-insect cell systems for recombinant glycoprotein production. We also discuss the use of these models as baselines for metabolic engineering efforts leading to the development of new baculovirus-insect cell systems with humanized protein N-glycosylation pathways, which can be used to produce more authentic recombinant N-glycoproteins for drug development and other biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.